EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Predictive Factors of Response to Neoadjuvant Chemotherapy (NACT) and Immune Checkpoint Inhibitors in Early-Stage Triple-Negative Breast Cancer Patients (TNBC)

Khashayar Yazdanpanah Ardakani, Francesca Fulvia Pepe, Serena Capici, Thoma Dario Clementi, Marina Elena Cazzaniga iD

Current Oncology · 2025

DOI: 10.3390/curroncol32070387 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Current Oncology, 2025. Verfasst von Khashayar Yazdanpanah Ardakani und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine and Surgery, University of Milano-Bicocca, 20900 Monza, Italy. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Neoadjuvant Therapy, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Triple-negative breast cancer (TNBC) is a heterogenous group of breast tumors. This type of breast tumor is relatively difficult to manage, due to the lack of expression of Hormone Receptors (HR) and human epidermal growth factor receptor (HER2). Efforts have been made to understand the factors involved in determining how a triple-negative breast tumor responds to therapy. The standard of treatment in most cases today is a combined modality of immune checkpoint inhibitors (ICIs) and chemotherapy with agents such as anti-mitotic (taxanes) or DNA-damaging agents (alkylating agents, cyclophosphamides, platin salts). In this study, we investigated the predictive and prognostic factors for TNBC, in the neoadjuvant setting; understanding each patient’s response before treatment initiation is crucial to guiding the subsequent approach and finally improving patient outcomes. We focused on tumor-infiltrating lymphocytes at the site of the primary tumor (TILs), circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), the mutational status of protein 53 (p53), and Ki-67, investigating the potential roles of these factors in predicting responses to anti-cancer agents.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Triple Negative Breast NeoplasmsNeoadjuvant TherapyImmune Checkpoint InhibitorsHumansFemalePrognosisMiddle AgedNeoplasm StagingLymphocytes, Tumor-Infiltrating

Stichwörter der Autor:innen

TNBCcirculating tumor DNAcirculating tumor cellsimmunotherapytriple-negative breast cancer

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • School of Medicine and Surgery, University of Milano-Bicocca, 20900 Monza, Italy.
  • Phase 1 Research Center, Fondazione IRCC San Gerardo dei Tintori, 20090 Monza, Italy.

ORCID-Profile: Marina Elena Cazzaniga

Zitieren

APA

Ardakani, K. Y., Pepe, F. F., Capici, S., Clementi, T. D., & Cazzaniga, M. E. (2025). Predictive Factors of Response to Neoadjuvant Chemotherapy (NACT) and Immune Checkpoint Inhibitors in Early-Stage Triple-Negative Breast Cancer Patients (TNBC). Current Oncology. https://doi.org/10.3390/curroncol32070387

Vancouver

Ardakani KY, Pepe FF, Capici S, Clementi TD, Cazzaniga ME. Predictive Factors of Response to Neoadjuvant Chemotherapy (NACT) and Immune Checkpoint Inhibitors in Early-Stage Triple-Negative Breast Cancer Patients (TNBC). Current Oncology. 2025. doi:10.3390/curroncol32070387

BibTeX
@article{Ardakani2025,
  author = {Ardakani, Khashayar Yazdanpanah and Pepe, Francesca Fulvia and Capici, Serena and Clementi, Thoma Dario and Cazzaniga, Marina Elena},
  title = {Predictive Factors of Response to Neoadjuvant Chemotherapy (NACT) and Immune Checkpoint Inhibitors in Early-Stage Triple-Negative Breast Cancer Patients (TNBC)},
  journal = {Current Oncology},
  year = {2025},
  doi = {10.3390/curroncol32070387}
}
Kostenlos starten →